Pharma Giants Clash with Germany Over Price Caps

Pfizer is reassessing its planned investments in Germany in response to governmental proposals to lower drug prices, joining other pharmaceutical firms like Eli Lilly and Boehringer Ingelheim in opposition. These developments highlight ongoing tensions between drugmakers and European governments over pricing regulations affected by U.S. policies.

Pfizer has announced that it is reviewing its planned investments in Germany, as outlined in a letter from CEO Albert Bourla to Chancellor Friedrich Merz. The American pharmaceutical giant is the latest in its industry to question government proposals aiming to reduce drug prices.

The June 9 letter, first reported by Handelsblatt and seen by Reuters, emphasizes the unpredictability these proposals introduce to pharmaceutical investments. Without specifying details, Pfizer indicated that projects may be delayed or altered.

This announcement follows similar decisions by Eli Lilly and Boehringer Ingelheim, highlighting a broader conflict between pharmaceutical companies and European governments over price caps, exacerbated by policy pressures from the U.S.